Mouwasat Medical Services - Drug News & Views

FIRST LOW-DOSE ORAL CHEWABLE CONTRACEPTIVE REGIMEN

(Find this article on the latest issue of PHARMACY NEWSLETTER)

December 27, 2010 - The US Food and Drug Administration (FDA) has approved the first low-dose oral contraceptive regimen to combine 0.8mg norethindrone and 0.025mg ethinyl estradiol in chewable form, with four 75-mg ferrous fumarate placebo tablets. The 24/4 regimen, marketed by Watson Pharmaceuticals, Inc. a subsidiary of Global Brands under license from Warner Chilcott plc, is intended to decrease breakthough bleeding and provide short, light, predictable periods...